Equities

Beijing Chunlizhengda Medical Instruments Co Ltd

Beijing Chunlizhengda Medical Instruments Co Ltd

Actions
  • Price (HKD)8.19
  • Today's Change-0.05 / -0.61%
  • Shares traded437.75k
  • 1 Year change-40.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024 06:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Beijing Chunlizhengda Medical Instruments Co Ltd's net income fell -9.72% from 307.72m to 277.82m despite flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 25.09% to 29.24%.
Gross margin71.08%
Net profit margin17.12%
Operating margin18.98%
Return on assets4.62%
Return on equity5.68%
Return on investment5.49%
More ▼

Cash flow in CNYView more

In 2023, Beijing Chunlizhengda Medical Instruments Co Ltd increased its cash reserves by 32.26%, or 308.82m. The company earned 511.71m from its operations for a Cash Flow Margin of 42.34%. In addition the company used 81.56m on investing activities and also paid 121.33m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share7.29
Tangible book value per share6.91
More ▼

Balance sheet in CNYView more

Beijing Chunlizhengda Medical Instruments Co Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 1.27bn.
Current ratio4.76
Quick ratio3.80
Total debt/total equity0.0003
Total debt/total capital0.0003
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)87.69%
EPS growth(5 years)18.66
EPS (TTM) vs
TTM 1 year ago
-41.77
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.